- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745940
Mindfulness-Based Cognitive Therapy Intervention to Treat Depression in Individuals With a Traumatic Brain Injury
A Multi-site, Randomized, Controlled Trial of a Mindfulness-based Cognitive Therapy Intervention for Treating Depression in a Traumatic Brain Injury Population.
The purpose of this study is to determine whether mindfulness-based cognitive therapy is effective in reducing depression symptoms in individuals who have experienced a traumatic brain injury.
The investigators hypothesize that participants who are given the ten-week intervention will have fewer depression symptoms than the participants in the control group, and this improvement will be maintained at the three-month follow-up assessment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8M2
- Ottawa Hospital Rehabilitation Centre
-
Thunder Bay, Ontario, Canada, P7B 5G7
- St. Joseph's Care Group
-
Toronto, Ontario, Canada, M5G 2A2
- Toronto Rehabilitation Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- traumatic brain injury suffered more than one year ago but less than five
- Evidence of depression post-traumatic brain injury (Beck Depression Inventory-II score of 16 or greater)
- Ability to speak and read English
- Age 18 or more
Exclusion Criteria:
- Inability to benefit from the intervention based a consensus process amongst study clinical psychologist and physicians, and from scores on memory and auditory attention (California Verbal Learning Test, Digit Span subsection of Wechsler Adult Intelligence Scale); verbal fluency and executive functioning (Controlled Oral Word Association Test); verbal abstract reasoning (Similarities subsection of Wechsler Adult Intelligence Scale); and executive functioning (Trail Making Test).
- Evidence of unusual psychological processes such as psychosis, suicidal ideation, substance abuse, or major concurrent mental illness (Beck Depression Inventory-II and Symptom Checklist-90-R will supplement the decision-making process of study clinicians).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MBCT Intervention Group
The curriculum of our mindfulness intervention draws upon elements from the mindfulness-based stress reduction program, and Segal and colleagues manual for mindfulness-based cognitive therapy.
It was modified by one of the investigators to address issues associated with traumatic brain injury (e.g., problems with attention, concentration, memory, fatigue).
The intervention was increased to ten weeks with one and a half hour weekly sessions, along with a 20-30 minute daily meditation home practice.
Further adaptations included simplified language, the use of repetition to reinforce concepts, and visual aids.
More attention was paid to fostering learning conditions to encourage an environment of trust and non-judgement.
Connections between learning activities was also made more explicit.
|
Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators.
Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression.
Subjects will be encouraged to practice skills at home and in daily life.
Other Names:
|
NO_INTERVENTION: MBCT Control Group
Control group waited.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Beck Depression Inventory - II
Time Frame: Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
The Beck Depression Inventory (BDI-II) is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
It assesses the intensity of depression into 4 categories ranging from minimal (scores from 0-13) to severe (scores from 29-63) (79).
Each item is a list of four statements arranged in increasing severity about a particular symptom of depression.
The depression criteria are consistent with those of the Diagnostic and Statistical Manual of Mental Health Disorders-Fourth Edition (DSM-IV).
The cognitive-affective factor includes items concerning sadness, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, worthlessness, and irritability.
The somatic factor is comprised of loss of energy, changes in sleeping pattern, changes in appetite, concentration difficulty, and tiredness or fatigue.
|
Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
The PHQ-9 is a self-administered questionnaire based on the PRIME-MD diagnostic instrument for common mental disorders.
Each of the 9 DSM-IV criteria is scored on a four point Likert scale ranging from "0" (not at all) to "3" (nearly every day) with higher scores indicative of greater depression symptoms.
Scores range from a low of 0 to a high of 27.
|
Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
Symptom Checklist-90 Revised (Depression Subscale)
Time Frame: Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
The Symptom Checklist-90 Revised (SCL-90-R) is a 90 item self-report questionnaire designed to measure nine primary symptom dimensions: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism from the last two weeks from the current point in time.
A five point Likert scale is used ranging from "Not at All" to "Extremely" with higher scores indicative of greater symptoms.
There are 13 questions in the depression subscale with scores ranging between 0 and 52.
To help with interpretation of all SCL-90-R sub-scales, we transformed this sub-scale total score back to a score between 0 to 4 with higher scores indicating greater depression symptoms.
|
Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
Philadelphia Mindfulness Scale (Awareness Subscale)
Time Frame: Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
The Philadelphia Mindfulness Scale (PHLMS) is a measure of mindfulness to assess present-moment awareness and acceptance.
The questionnaire comprises 20 questions rated on a five-point Likert scale with higher scores indicative of greater mindfulness.
It comprises two subscales - Awareness and Acceptance.
The range of scores on the Awareness subscale is 10 to 50 and the range on the Acceptance subscale is 10 to 50 with higher scores indicative a greater awareness and acceptance respectively.
|
Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
Philadelphia Mindfulness Scale (Acceptance Subscale)
Time Frame: Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
The Philadelphia Mindfulness Scale (PHLMS) is a measure of mindfulness to assess present-moment awareness and acceptance.
The questionnaire comprises 20 questions rated on a five-point Likert scale with higher scores indicative of greater mindfulness.
It comprises two subscales - Awareness and Acceptance.
The range of scores on the Awareness subscale is 10 to 50 and the range on the Acceptance subscale is 10 to 50 with higher scores indicative a greater awareness and acceptance respectively.
|
Baseline data were collected prior to the intervention and post-intervention data were collected 10 weeks later.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michel Bédard, PhD, Lakehead University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABI-MIND2-476
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on MBCT for TBI
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompleted
-
Massachusetts General HospitalCompletedDepression | Myocardial Infarction | Acute Coronary Syndrome | Unstable Angina | STEMI | NSTEMI - Non-ST Segment Elevation MIUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, PulmonaryUnited States
-
University GhentCompletedSuicidal Ideation | Suicide AttemptBelgium
-
NYU Langone HealthNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Centre for Interdisciplinary Research in Rehabilitation...Fonds de la Recherche en Santé du QuébecRecruitingTraumatic Brain InjuryCanada
-
Clinique Romande de ReadaptationActive, not recruitingTBI (Traumatic Brain Injury)Switzerland
-
Radboud University Medical CenterRecruitingParkinson's DiseaseNetherlands